Neoadjuvant immune checkpoint inhibitors for hepatocellular carcinoma
Vinita Akula, Lily Chen, Yusuf Açıkgöz, Katherine J. Klein, Betül Gök Yavuz, Lokman Çevik, Tarık Demir, Ashish Manne, İlyas Şahin, Ahmed O. Kaseb, Elshad Hasanov
Abstract
Hepatocellular carcinoma (HCC) is the most common type of liver cancer. HCC treatment is challenging; surgical resection is the primary curative treatment for early-stage disease, but recurrence rates are high. Immune checkpoint inhibitors (ICIs) are a promising neoadjuvant treatment that can reduce recurrence rates and mortality after surgery and achieve complete/partial responses. Clinical trials provide strong evidence for the efficacy and safety of ICI monotherapy for neoadjuvant HCC treatment.
Topics & Concepts
Hepatocellular carcinomaImmune checkpointCancer researchMedicineOncologyImmune systemInternal medicineImmunotherapyImmunologyHepatocellular Carcinoma Treatment and PrognosisCancer Immunotherapy and BiomarkersCancer Mechanisms and Therapy